

Halfdan Sorbye

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5809200/publications.pdf>

Version: 2024-02-01

86
papers

6,703
citations

159585

30
h-index

76900

74
g-index

87
all docs

87
docs citations

87
times ranked

7452
citing authors

#	ARTICLE	IF	CITATIONS
1	Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. <i>Lancet</i> , The, 2008, 371, 1007-1016.	13.7	1,759
2	Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1208-1215.	10.7	1,017
3	Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 1755-1762.	1.6	482
4	A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. <i>Journal of Controlled Release</i> , 2016, 243, 172-181.	9.9	332
5	Gastroenteropancreatic high-grade neuroendocrine carcinoma. <i>Cancer</i> , 2014, 120, 2814-2823.	4.1	277
6	Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. <i>Cancer</i> , 2011, 117, 4617-4622.	4.1	233
7	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology - Diagnosis and Prognostic Stratification. <i>Neuroendocrinology</i> , 2017, 105, 196-200.	2.5	178
8	Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. <i>Cancer</i> , 2018, 124, 807-815.	4.1	169
9	Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. <i>Cancer</i> , 2009, 115, 4679-4687.	4.1	128
10	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. <i>Neuroendocrinology</i> , 2017, 105, 266-280.	2.5	122
11	Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. <i>Endocrine-Related Cancer</i> , 2019, 26, 227-239.	3.1	114
12	Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. <i>Acta Oncologica</i> , 2014, 53, 1284-1297.	1.8	99
13	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy. <i>Neuroendocrinology</i> , 2017, 105, 281-294.	2.5	94
14	Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983). <i>Annals of Surgery</i> , 2012, 255, 534-539.	4.2	91
15	High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort. <i>PLoS ONE</i> , 2015, 10, e0131046.	2.5	91
16	Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 147 controlled trial. <i>BMC Surgery</i> , 2017, 17, 94.	1.3	84
17	Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. <i>International Journal of Cancer</i> , 2016, 139, 647-656.	5.1	79
18	PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). <i>Endocrine-Related Cancer</i> , 2020, 27, R67-R77.	3.1	79

#	ARTICLE	IF	CITATIONS
19	Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. <i>European Journal of Cancer</i> , 2016, 63, 11-24.	2.8	73
20	Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 1721-1728.	1.5	73
21	Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. <i>European Journal of Cancer</i> , 2015, 51, 2708-2717.	2.8	72
22	Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection. <i>PLoS Genetics</i> , 2016, 12, e1006225.	3.5	64
23	Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). <i>Neuroendocrinology</i> , 2019, 108, 54-62.	2.5	62
24	The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2022, 29, 1-14.	3.1	62
25	Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. <i>Oncotarget</i> , 2016, 7, 75013-75022.	1.8	61
26	The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 683-698.	3.2	58
27	Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study. <i>British Journal of Cancer</i> , 2017, 116, 1271-1278.	6.4	55
28	A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations. <i>Neuroendocrinology</i> , 2021, 111, 883-894.	2.5	54
29	Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. <i>British Journal of Cancer</i> , 2018, 118, 1609-1616.	6.4	47
30	Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 376-388.	8.1	43
31	Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. <i>Acta Oncologica</i> , 2021, 60, 931-941.	1.8	32
32	Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer. <i>Oncotarget</i> , 0, 7, 41948-41958.	1.8	30
33	Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases. <i>World Journal of Surgical Oncology</i> , 2015, 13, 328.	1.9	29
34	Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?. <i>Gut</i> , 2021, 70, 1768-1781.	12.1	28
35	EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3508-3508.	1.6	27
36	High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. <i>PLoS ONE</i> , 2017, 12, e0182512.	2.5	27

#	ARTICLE	IF	CITATIONS
37	Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2020, 110, 217-224.	2.5	25
38	Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. <i>PLoS ONE</i> , 2017, 12, e0187667.	2.5	24
39	Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine–non-neuroendocrine neoplasms. <i>Journal of Neuroendocrinology</i> , 2021, 33, e12967.	2.6	23
40	Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis. <i>Acta Oncologica</i> , 2020, 59, 417-426.	1.8	22
41	Recurrence Patterns After Resection of Liver Metastases from Colorectal Cancer. <i>Recent Results in Cancer Research</i> , 2014, 203, 243-252.	1.8	20
42	Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study. <i>PLoS ONE</i> , 2014, 9, e87746.	2.5	18
43	KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 826073.	2.8	15
44	Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas. <i>Oncologist</i> , 2022, 27, 299-306.	3.7	14
45	Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. <i>European Journal of Cancer</i> , 2017, 81, 26-35.	2.8	13
46	Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. <i>BMC Cancer</i> , 2017, 17, 548.	2.6	13
47	Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). <i>Medical Oncology</i> , 2018, 35, 47.	2.5	13
48	Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study. <i>Cancers</i> , 2021, 13, 2604.	3.7	13
49	Modeling and Validating the Cost and Clinical Pathway of Colorectal Cancer. <i>Medical Decision Making</i> , 2015, 35, 255-265.	2.4	12
50	ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13040.	2.6	12
51	Volumetric parameters from [¹⁸ F]FDG PET/CT predicts survival in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms. <i>Journal of Neuroendocrinology</i> , 2022, 34, .	2.6	12
52	Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study. <i>Acta Oncologica</i> , 2020, 59, 284-290.	1.8	11
53	Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 395-405.	2.8	10
54	Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach. <i>European Journal of Health Economics</i> , 2020, 21, 321-334.	2.8	10

#	ARTICLE	IF	CITATIONS
55	Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with <i>RAS</i> -mutated or <i>BRAF</i> -mutated metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2021, 149, 1385-1397.	5.1	10
56	Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Initial results from the randomized METIMMOX study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3556-3556.	1.6	9
57	Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. <i>International Journal of Cancer</i> , 2015, 137, 2470-2477.	5.1	8
58	Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review. <i>Acta Oncologica</i> , 2016, 55, 881-885.	1.8	8
59	A Plasma Protein Biomarker Strategy for Detection of Small Intestinal Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2021, 111, 840-849.	2.5	8
60	Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3. <i>Scientific Reports</i> , 2020, 10, 10639.	3.3	8
61	Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small-intestinal neuroendocrine tumours. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 188.	2.4	7
62	TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in <i>KRAS</i> -mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer. <i>Oncotarget</i> , 2016, 7, 59441-59457.	1.8	7
63	Palliative chemotherapy in elderly patients with metastatic colorectal cancer: Do we know how it should be used?. <i>Acta Oncologica</i> , 2012, 51, 819-821.	1.8	6
64	Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal poorly differentiated neuroendocrine carcinoma: The NORDIC NEC study. <i>Journal of Clinical Oncology</i> , 2012, 30, 4015-4015.	1.6	5
65	Drug costs and benefits of medical treatments in high-unmet need solid tumours in the Nordic countries. <i>Journal of Cancer Policy</i> , 2016, 7, 12-22.	1.4	4
66	Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors. <i>Journal of Neuroendocrinology</i> , 2022, 34, .	2.6	4
67	Maintenance therapy with biweekly cetuximab (C) in the first-line treatment of metastatic colorectal cancer (mCRC): The NORDIC 7.5 study (NCT00660582), by the Nordic Colorectal Cancer Biomodulation Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 3538-3538.	1.6	2
68	Ultrasound and microbubble enhanced treatment of inoperable pancreatic adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, e15703-e15703.	1.6	2
69	Survival according to mutations in BRAF, KRAS, or microsatellite instability (MSI-H) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastases from colorectal cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3565-3565.	1.6	2
70	Feasibility of switching to S-1 after other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 7037-7037.	1.6	2
71	FLOX regimen (5-FU, folinic acid, oxaliplatin) and FLIRI regimen (5-FU, folinic acid, irinotecan) as first-line treatment in metastatic and locally advanced gastric cancer: A randomized phase II study. <i>Journal of Clinical Oncology</i> , 2012, 30, 71-71.	1.6	1
72	Intra-individual genetic heterogeneity among liver metastases in metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 555-555.	1.6	1

#	ARTICLE	IF	CITATIONS
73	Pre-planned safety analysis of NORDIC 9: A randomized trial comparing full dose monotherapy (S-1) with reduced dose combination therapy (S-1/oxaliplatin) in older chemo-naive patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2017, 35, 10032-10032.	1.6	1
74	Feminizing adrenal tumor identified by plasma steroid profiling. Endocrinology, Diabetes and Metabolism Case Reports, 2021, 2021, .	0.5	1
75	Reply to Letter. Annals of Surgery, 2015, 261, e29.	4.2	0
76	Abstract 522: Immunogenic chemotherapy and immune checkpoint inhibition (ICI) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Biomarkers indicative of durable treatment response. , 2021, , .		0
77	Plasma concentrations of YKL-40 in chemo-naive patients with metastatic colorectal cancer treated with FLOX with or without cetuximab: Results from the NORDIC VII study.. Journal of Clinical Oncology, 2012, 30, 3548-3548.	1.6	0
78	Plasma levels of TIMP-1 in chemo-naive patients with metastatic colorectal cancer treated with first-line FLOX with or without cetuximab: Results from the Nordic VII Study.. Journal of Clinical Oncology, 2013, 31, 392-392.	1.6	0
79	Plasma TIMP-1 in patients with metastatic colorectal cancer treated with first-line oxaliplatin-based therapy with or without cetuximab: Results from the Nordic VII study.. Journal of Clinical Oncology, 2013, 31, e14710-e14710.	1.6	0
80	Prognostic significance of tumor stromal and epithelial claudin 2 in metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 3597-3597.	1.6	0
81	Tumor perivascular PDGFBR as an independent prognostic factor in metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 3571-3571.	1.6	0
82	Digitalized multiparametric analyses of tumor stroma for identification of low perivascular PDGFBR expression and low vessel density as independent prognosis markers for stage IV CRC.. Journal of Clinical Oncology, 2014, 32, e14525-e14525.	1.6	0
83	C-reactive protein and interleukin-6 as markers of systemic inflammatory response and as prognostic factors for metastatic colorectal cancer. Data from the randomized phase III NORDIC-VII study.. Journal of Clinical Oncology, 2015, 33, 3548-3548.	1.6	0
84	Prognostic significance of SATB1 expression in metastatic colorectal cancer: A Nordic prospective cohort study.. Journal of Clinical Oncology, 2018, 36, 707-707.	1.6	0
85	Expression of podocalyxin-like protein and epidermal growth factor receptor in metastatic colorectal cancer: Prognostic impact and relationship with response to cetuximab.. Journal of Clinical Oncology, 2018, 36, e15587-e15587.	1.6	0
86	Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer. Cancer Treatment and Research Communications, 2022, 31, 100517.	1.7	0